Effects of caffeine on exercise performance based on genetic factors
Influence of CYP1A2 on the Acute Effect of Caffeine Intake on Resistance Exercise
NA · University of Alcala · NCT06610110
This study is testing how caffeine affects exercise performance in young, active people based on their genetics.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 35 Years |
| Sex | All |
| Sponsor | University of Alcala (other) |
| Locations | 2 sites (Alcalá de Henares, Madrid and 1 other locations) |
| Trial ID | NCT06610110 on ClinicalTrials.gov |
What this trial studies
This study investigates how the CYP1A2 genetic polymorphism affects the performance-enhancing effects of acute caffeine intake during resistance exercise. It aims to analyze muscular strength, power, and endurance in physically active men and women aged 18 to 35 with a BMI under 25. Participants will receive either caffeine or a placebo and undergo performance tests to determine the impact of their genetic makeup on exercise outcomes.
Who should consider this trial
Good fit: Ideal candidates are healthy men and women aged 18 to 35 who are physically active and have a BMI under 25.
Not a fit: Patients with a BMI of 25 or higher, or those with certain medical conditions affecting exercise performance, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help tailor caffeine supplementation strategies for improved athletic performance based on individual genetic profiles.
How similar studies have performed: Previous studies have shown positive effects of caffeine on exercise performance, but the specific focus on CYP1A2 polymorphism is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between ≥ 18 and ≤ 35 years. * Body mass index (BMI) lower than 25 kg/m². * Physically active subjects (≥150 min/week of moderate exercise). * Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise. * Participants capable of performing the tests. Exclusion Criteria: * History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism. * Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study. * Body mass index (BMI) ≥ 25 kg/m². * Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. * Performing strenuous exercise within 48 hours prior to the tests. * Failing to replicate the same food intake on the two experimental days. * Consuming caffeine after 6 PM on the day prior to training or testing.
Where this trial is running
Alcalá de Henares, Madrid and 1 other locations
- Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá — Alcalá de Henares, Madrid, Spain (RECRUITING)
- Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá — Alcalá de Henares, Madrid, Spain (RECRUITING)
Study contacts
- Study coordinator: Alberto Pérez-López, PhD
- Email: alberto.perezl@uah.es
- Phone: 34 918854537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: CYP1A2 Polymorphism, Caffeine and Resistance Exercise